Puget Technologies (PUGE) has revealed that its subsidiary company, Cannabis Biotech, has entered into an agreement with a patent attorney as it launches its product research to develop a system for the delivery of medical marijuana that uses the body's mucous membranes, such as the nasal passages.
Cannabis Biotech is developing the system to serve the growing medical marijuana patient base who want to use medical marijuana but do not want to smoke it.
Aside from smoking, eating products that contain THC is the only other viable way for many people to use medical marijuana, but it takes much longer to take effect when eaten.
Nasal delivery for the administration of therapeutic remedies has been used for thousands of years and is very popular today," says Ken Morrow, prominent international marijuana authority and head of the research group for Cannabis Biotech. "The system offers the potential of appealing to a broader patient base due to being user-friendly, reliable and fast-acting.
According to Research and Markets, a leading international source for international market research reports and market data, the global drug delivery market was worth $142.5 billion in 2012. It's a market that President and CEO of Puget Technologies Ron Leyland says the company feels it can tap into with a nasal delivery system for medical marijuana, similar to some cold and allergy medications that are administered via the nasal passages.
Cannabis Biotech will be filing a design patent for a unique delivery device to optimize the administration of the medicine and improve effectiveness and outcomes, Leyland says. The intranasal system will position Cannabis Biotech to take advantage of market growth and play a significant role in the future of medical marijuana development and commercialization.
The use of medical marijuana, though potentially beneficial for some, may negatively affect the workplace. Employers who are concerned about the marijuana phenomenon can opt for marijuana drug test kits for instant detection of drug use.